Cellectis Logo.png
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
03 févr. 2023 09h33 HE | Cellectis Inc.
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Logo.png
Cellectis Announces Pricing of Follow-On Offering
03 févr. 2023 00h48 HE | Cellectis Inc.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Logo.png
Cellectis Announces Launch of Follow-On Offering
02 févr. 2023 16h01 HE | Cellectis Inc.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Logo.png
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
20 janv. 2023 16h30 HE | Cellectis Inc.
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Logo.png
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
17 janv. 2023 07h10 HE | Cellectis Inc.
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and...
Global Cellular Immunotherapy Market
Cellular Immunotherapy (CAR T Cell Therapy, Dendritic Cell Therapy) Market Trends/Analysis Report 2022
06 janv. 2023 06h03 HE | Research and Markets
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), by...
22157.jpg
Global CAR-T Cell Therapy Market Report 2023: Remarkable Efficacy of CAR-T Therapy Against Blood Cancers Fuels Adoption
04 janv. 2023 07h38 HE | Research and Markets
Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2023" report has been added to ResearchAndMarkets.com's offering. ...
CAR T-Cell Therapy Market
Insights on the CAR T-Cell Therapy Global Market to 2031 - by Drug Type, Indication, End-user and Region
04 janv. 2023 05h48 HE | Research and Markets
Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "CAR T-Cell therapy Market By Drug type, By Indication, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added...
Cellectis Logo.png
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
28 déc. 2022 16h30 HE | Cellectis Inc.
The credit facility will enable Cellectis to support the development of its UCART product candidates pipelineThe credit facility consists of three tranches of €20 million, €15 million, and €5 million...
Picture1.png
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
21 déc. 2022 16h01 HE | Autolus Therapeutics plc
LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today...